Nanjing Vazyme Biotech Co., Ltd. Class ASSE: 688105

"NANJING VAZYME BIOTECH CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026

Sep 24, 2026 · Issued by Nanjing Vazyme Biotech Co., Ltd. Class A via Shanghai Stock Exchange

Notice on Convening the 2nd Extraordinary General Meeting in 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Nanjing Vazyme Biotech Co., Ltd. Class A

"NANJING VAZYME BIOTECH CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO IndustryAug 28
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue GrowthAug 26
"NANJING VAZYME BIOTECH CO., LTD."Indicative Announcement on Change in Equity Interests of a Shareholder Holding More Than 5% of Shares Reaching the 1% and 5% Thresholds and Disclosure of Simplified Report on Changes in Equity InterestsJul 29
"NANJING VAZYME BIOTECH CO., LTD."Indicative Announcement on Progress of Shareholding Increase by the Controlling Shareholder and Equity Change Reaching the 1% ThresholdJul 25

All Nanjing Vazyme Biotech Co., Ltd. Class A news releases